| abstract |
The invention relates to a pharmaceutical composition, a therapeuticncombination product and a kit comprising a sterically hindered platinum coordinationncompound and a non-platinum based anti-cancer agent and a pharmaceutically-acceptablencarrier or diluent; to the use thereof for the manufacture of a medicamentnfor inhibiting the growth of tumour cells in a human afflicted therewith; to a methodnof inhibiting the growth of tumour cells in a human afflicted therewith whichncomprises administering to such human an effective tumour cell growth inhibitingnamount of such a therapeutic combination product or of a pharmaceuticalncomposition of the invention; in particular when the sterically hindered platinumncoordination compound is (SP-4-3)-(cis)-am-minedichloro-[2-methylpyridine]platinumn(II), or a pro-drug thereof, and the non-platinum based anti-cancernagent is selected from Taxol Gemcitabine, Navelbine, Doxil, 5-FU andnTaxotere. |